Topic: drug sales

Dupixent grew sales by 28% sequentially at constant currencies, to €225 million, and that doesn't even count a recent major approval in asthma.

With its Trulance launch on the skids, Synergy is running out of cash and needs to win new debt terms to avoid bankruptcy.

With its new use in gMG, Soliris volume grew 24% year-over-year to a third-quarter haul of $888 million.

Novartis is raising its 2018 sales outlook, but canakinumab won’t help it hit the new target—at least not in the cardiovascular sales department.

Roche’s blockbuster cancer trio held their ground so far this year despite biosimilar rivals in the EU, thanks to growth in the U.S. and China.

J&J could suffer a big patent loss for Zytiga, but even if that happens, the company argues it can grow faster than its peers.

GSK's Nucala took a big hit Friday when the FDA stiff-armed its hoped-for new approval in COPD, which could have boosted sales significantly.

Shire got a brand-new approval that could help it dominate the hereditary angioedema market for years—and rack up blockbuster sales in the process.

BMS and Pfizer’s Eliquis and J&J and Bayer’s Xarelto will lead the pack in 2024, followed by Amgen’s Repatha, Novartis’ Entresto and J&J's Uptravi.

Lenvima's quarterly sales grow to $106 million; China makes 48-drug list for streamlined review; Samsung commits further investment in biologics.